Last reviewed · How we verify
SODAS MPH
SODAS MPH is a sustained-release formulation of methylphenidate designed to provide extended therapeutic coverage for attention-deficit/hyperactivity disorder (ADHD) symptoms throughout the day.
SODAS MPH is a sustained-release formulation of methylphenidate designed to provide extended therapeutic coverage for attention-deficit/hyperactivity disorder (ADHD) symptoms throughout the day. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults.
At a glance
| Generic name | SODAS MPH |
|---|---|
| Also known as | Ritalin LA |
| Sponsor | Massachusetts General Hospital |
| Drug class | Psychostimulant; extended-release methylphenidate |
| Target | Dopamine transporter (DAT) and norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
SODAS MPH (Spheroidal Oral Drug Absorption System) uses a proprietary microencapsulation technology to deliver methylphenidate in a biphasic release pattern—an initial immediate release followed by a sustained release phase. This allows for once-daily dosing while maintaining consistent plasma concentrations of the stimulant, which enhances dopamine and norepinephrine availability in the central nervous system to improve attention and impulse control.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adults
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness or anxiety
- Tachycardia
- Elevated blood pressure
Key clinical trials
- Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist (PHASE4)
- A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults (PHASE4)
- Impact of Attention Deficit/Hyperactivity Disorder and Substance Use Disorder on Motorcycle Traffic Accidents (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SODAS MPH CI brief — competitive landscape report
- SODAS MPH updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI